- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Christine Simmon Talks Uptake Patterns: Biosimilars vs Generics
Christine Simmon talks about whether or not biosimilar uptake will happen as rapidly as it did for generics at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.
Christine Simmon, JD, is the senior vice president of policy and strategic alliances for the Association for Accessible Medicines (AAM) and the executive director of AAM’s Biosimilars Council.
Transcript:
Will biosimilars be utilized to the same degree as generics?
To answer your question as to whether we will see the same level of uptake for biosimilars that we've seen in the generic realm, I think the jury's still out. These are more complex products. They are more costly to manufacture. They do require a higher level of investment and I think, most importantly, they are not, per se, interchangeable. I'm sure you know that the 90% dispensing rate that currently occurs in the United States for generic products is basically predicated on their automatic substitutability, which is, of course, a byproduct of being interchangeable. With biosimilars, the interchangeability that is unique to the United States is a separate designation that has to be achieved. So, I don't think we'll see [fast biosimilar uptake]. Certainly not as rapidly [as generics]. It's a longer-term play, and we'll have to wait and see.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
